Immuneering Corporation (IMRX) Free Cash Flow by Year
Immuneering Corporation recorded an outflow of $45.5M in free cash flow in fiscal year 2025. This represents an increase of 17.4% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to an outflow of $57.0M in free cash flow. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Immuneering Corporation has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
IMRX Free Cash Flow by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
IMRX Free Cash Flow by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What free cash flow means
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.
More Immuneering Corporation financials
Frequently Asked Questions
What was Immuneering Corporation's free cash flow in fiscal year 2025?
Immuneering Corporation recorded an outflow of $45.5M in free cash flow in fiscal year 2025.
How fast is Immuneering Corporation's free cash flow growing?
Immuneering Corporation (IMRX) free cash flow rose by 17.4% year over year, from -$55.1M to -$45.5M in fiscal year 2025.
What is Immuneering Corporation's free cash flow over the last twelve months?
Immuneering Corporation (IMRX) reported an outflow of $57.0M in free cash flow over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Immuneering Corporation's free cash flow changed over the years?
Across the 6 fiscal years this page covers, Immuneering Corporation (IMRX) free cash flow went from -$14.7M in fiscal year 2020 to -$45.5M in fiscal year 2025.
What was Immuneering Corporation's free cash flow in the most recent quarter?
Immuneering Corporation (IMRX) reported -$16.5M in free cash flow in Q2 2026. This represents a decrease of 74.9% from the same quarter a year earlier.
What does free cash flow mean on a financial statement?
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Immuneering Corporation (IMRX) reported on that line in every period on record.